Protective roles of hydroxyethyl starch 130/0.4 in intestinal inflammatory response and survival in rats challenged with polymicrobial sepsis

Clin Chim Acta. 2007 Feb;376(1-2):60-7. doi: 10.1016/j.cca.2006.07.008. Epub 2006 Jul 14.

Abstract

Background: The gut is considered an important target organ of injury after severe insult such as sepsis, trauma and shock. Hydroxyethyl starch (HES) 130/0.4 has been developed to improve the pharmacokinetics of current medium molecular weight HES solutions. We investigated the protective effects of HES 130/0.4 on intestinal inflammatory response and survival in a rat polymicrobial sepsis model induced by cecal ligation and puncture.

Methods: Animals were treated with HES 130/0.4 or saline at 4, 10, 16 or 22 h after the induction of sepsis or sham-operation and were sacrificed 2 h after resuscitation. Intestines were harvested for measurement of tumour necrosis factor alpha (TNF-alpha), interleukin (IL)-10 and macrophage inflammatory protein-2 (MIP-2) production by EELISA; intercellular adhesion molecule-1 (ICAM-1) mRNA expression by reverse-transcription PCR; nuclear factor-kappa B (NF-kappaB) by electrophoretic mobility shift assay; neutrophil sequestration by myeloperoxidase (MPO) assay; intestinal permeability by fluorescein isothiocyanate-labeled dextran assay. In addition, the role of HES 130/0.4 in rat survival was observed.

Results: Intestinal permeability was significantly decreased after HES 130/0.4 administration in septic rats, which was associated with a reduction in inflammatory mediators and NF-kappaB activation. Furthermore, early administration of HES 130/0.4 after septic insult resulted in greater decrease in inflammatory mediators. In addition, HES 130/0.4 co-administrated with antibiotics not HES 130/0.4 alone greatly improved the survival of septic rats.

Conclusions: HES 130/0.4 reduced intestinal permeability by modulating inflammatory response and had a promising effect on survival together with antibiotics under septic conditions.

MeSH terms

  • Animals
  • Anti-Bacterial Agents / therapeutic use
  • Disease Models, Animal
  • Disease Progression
  • Hydroxyethyl Starch Derivatives / therapeutic use*
  • Inflammation Mediators / metabolism*
  • Infusions, Intravenous
  • Intercellular Adhesion Molecule-1 / genetics
  • Intercellular Adhesion Molecule-1 / metabolism
  • Intestinal Mucosa / metabolism
  • Intestines / drug effects*
  • Intestines / immunology*
  • Male
  • NF-kappa B / metabolism
  • Permeability / drug effects
  • Peroxidase / metabolism
  • RNA, Messenger / analysis
  • RNA, Messenger / biosynthesis
  • Rats
  • Rats, Sprague-Dawley
  • Sepsis / drug therapy*
  • Survival Rate

Substances

  • Anti-Bacterial Agents
  • Hydroxyethyl Starch Derivatives
  • Inflammation Mediators
  • NF-kappa B
  • RNA, Messenger
  • Intercellular Adhesion Molecule-1
  • Peroxidase